Literature DB >> 20508003

Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine.

Tine Dalby1, Jesper Westphal Petersen2, Zitta B Harboe1, Karen Angeliki Krogfelt1.   

Abstract

The measurement of IgG anti-pertussis toxin (IgG anti-PT) antibodies by ELISA is a frequently used method for studying the antibody responses after pertussis vaccination and after Bordetella pertussis infection. Such responses vary according to the different vaccines used as well as to the immunization and infection history of the participants. In the present study, the decay kinetics of the IgG anti-PT antibody response was determined for 71 Danish children and adults with bacteriologically confirmed B. pertussis infection and for 20 Danish adults booster-vaccinated with an acellular pertussis vaccine. For both groups, biphasic decay was seen, but the individual antibody responses varied greatly. No differences related to age were seen. Within each group, individual decay profiles showed parallel log-linear decay for the late part of the response. Antibody half-life was calculated for the late, slower part of the biphasic response curves for both groups (>5 months after diagnosis for individuals with confirmed infection; >3 months for vaccinated individuals). The median half-life for post-infection antibodies was 221 days [interquartile range (IQR) 159-314 days, 36 individuals], and the median half-life for post-vaccination antibodies was 508 days (IQR 428-616 days, 14 individuals). This difference was statistically significant (P<0.0001). Thus, in this setting, we found that the IgG anti-PT antibody decay after an infection with B. pertussis is more than twice as fast as the decay after booster vaccination with an acellular pertussis vaccine. Such knowledge of the IgG anti-PT decay kinetics is crucial for interpretation of serological data that will be used either for diagnosis or for epidemiological studies and surveillance of B. pertussis infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508003     DOI: 10.1099/jmm.0.020826-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  38 in total

1.  Seroprevalence of pertussis among Danish patients with cough of unknown etiology.

Authors:  Tine Dalby; Zitta B Harboe; Karen Angeliki Krogfelt
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

Review 2.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

3.  Does tetanus-diphtheria-acellular pertussis vaccination interfere with serodiagnosis of pertussis infection?

Authors:  Lucia C Pawloski; Kathryn B Kirkland; Andrew L Baughman; Monte D Martin; Elizabeth A Talbot; Nancy E Messonnier; Maria Lucia Tondella
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

4.  Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.

Authors:  Jamie N Sutherland; Christine Chang; Sandra M Yoder; Michael T Rock; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

5.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.

Authors:  Ricardo da Silva Antunes; Mariana Babor; Chelsea Carpenter; Natalie Khalil; Mario Cortese; Alexander J Mentzer; Grégory Seumois; Christopher D Petro; Lisa A Purcell; Pandurangan Vijayanand; Shane Crotty; Bali Pulendran; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

6.  Serum immunoglobulin G analysis to establish a delayed diagnosis of chronic cough due to Bordetella pertussis.

Authors:  Jonathan M Bock; Charles C Burtis; David M Poetker; Joel H Blumin; Michael O Frank
Journal:  Otolaryngol Head Neck Surg       Date:  2011-10-10       Impact factor: 3.497

7.  Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays.

Authors:  Aditi Kapasi; Bruce D Meade; Brian Plikaytis; Lucia Pawloski; Monte D Martin; Sandra Yoder; Michael T Rock; Séverine Coddens; Valérie Haezebroeck; Françoise Fievet-Groyne; Garvin Bixler; Charles Jones; Stephen Hildreth; Kathryn M Edwards; Nancy E Messonnier; Maria L Tondella
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

Review 8.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

Review 9.  Laboratory Diagnosis of Pertussis.

Authors:  Anneke van der Zee; Joop F P Schellekens; Frits R Mooi
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 10.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.